Vibrant Therapeutics lands $61m round joined by Pfizer Ventures
Chinese-US biotech Vibrant Therapeutics said it has raised $61 million in new financing, taking total capital raised to $100 million. New investors include Pfizer Ventures and Apricot Capital, alongside Bayland Capital, HSG, Northern Light Venture Capital, and First Principle Venture Limited.
Vibrant also appointed Han Lee as co-chief executive officer alongside founder Larry Wang. Separately, the US regulator accepted the Investigational New Drug application for VIB305, enabling the company to initiate US clinical studies as it seeks to run a more globally aligned development program.
The company said the proceeds will be used to advance its pipeline, further develop its drug design platform, and expand its team to support growth and global development activities. It also said Michael Diem, Trency Gu, and Zhen Zhang will join the board.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze